A Multicenter, Open-label Phase II Study of SyB L-0501 in Patients With Chronic Lymphocytic Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Aug 2016 Acording to Eisai media release, the Ministry of Health, Labour and Welfare approved bendamustine [Treakisym] 100 mg injection for chronic lymphocytic leukaemia in Japan. SymBio Pharmaceuticals filed an application in December 2015, after receiving a development request from the Japanese Ministry of Health, Labour and Welfare's Study Group on Unapproved and Off Label Drugs.
24 Dec 2015 According to a SymBio Pharmaceuticals media release, the company submitted the supplemental New Drug Application to the Pharmaceuticals and Medical Devices Agency in Japan for bendamustine [Treakisym] for chronic lymphocytic leukaemia.
19 Oct 2015 Status changed from active, no longer recruiting to completed, according to a SymBio Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com